295 related articles for article (PubMed ID: 28662200)
1. Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin.
Yamasaki K; Hyodo S; Taguchi K; Nishi K; Yamaotsu N; Hirono S; Chuang VTG; Seo H; Maruyama T; Otagiri M
PLoS One; 2017; 12(6):e0180404. PubMed ID: 28662200
[TBL] [Abstract][Full Text] [Related]
2. Interactive binding to the two principal ligand binding sites of human serum albumin: effect of the neutral-to-base transition.
Yamasaki K; Maruyama T; Yoshimoto K; Tsutsumi Y; Narazaki R; Fukuhara A; Kragh-Hansen U; Otagiri M
Biochim Biophys Acta; 1999 Jul; 1432(2):313-23. PubMed ID: 10407153
[TBL] [Abstract][Full Text] [Related]
3. Metal-catalyzed oxidation of human serum albumin does not alter the interactive binding to the two principal drug binding sites.
Yamasaki K; Nishi K; Anraku M; Taguchi K; Maruyama T; Otagiri M
Biochem Biophys Rep; 2018 Jul; 14():155-160. PubMed ID: 29872747
[TBL] [Abstract][Full Text] [Related]
4. Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin.
Sakai T; Yamasaki K; Sako T; Kragh-Hansen U; Suenaga A; Otagiri M
Pharm Res; 2001 Apr; 18(4):520-4. PubMed ID: 11451040
[TBL] [Abstract][Full Text] [Related]
5. Characterization of site I on human serum albumin: concept about the structure of a drug binding site.
Yamasaki K; Maruyama T; Kragh-Hansen U; Otagiri M
Biochim Biophys Acta; 1996 Jul; 1295(2):147-57. PubMed ID: 8695640
[TBL] [Abstract][Full Text] [Related]
6. The location of the high- and low-affinity bilirubin-binding sites on serum albumin: ligand-competition analysis investigated by circular dichroism.
Goncharova I; Orlov S; Urbanová M
Biophys Chem; 2013; 180-181():55-65. PubMed ID: 23838624
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin.
Ryan AJ; Ghuman J; Zunszain PA; Chung CW; Curry S
J Struct Biol; 2011 Apr; 174(1):84-91. PubMed ID: 20940056
[TBL] [Abstract][Full Text] [Related]
8. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism.
Okabe N; Hashizume N
Biol Pharm Bull; 1994 Jan; 17(1):16-21. PubMed ID: 8148809
[TBL] [Abstract][Full Text] [Related]
9. Study on the interaction of levocetirizine dihydrochloride with human serum albumin by molecular spectroscopy.
Liu X; Du Y; Sun W; Kou J; Yu B
Spectrochim Acta A Mol Biomol Spectrosc; 2009 Dec; 74(5):1189-96. PubMed ID: 19857990
[TBL] [Abstract][Full Text] [Related]
10. Circular dichroism spectroscopic detection of ligand binding induced subdomain IB specific structural adjustment of human serum albumin.
Zsila F
J Phys Chem B; 2013 Sep; 117(37):10798-806. PubMed ID: 24004247
[TBL] [Abstract][Full Text] [Related]
11. Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen.
Yamasaki K; Rahman MH; Tsutsumi Y; Maruyama T; Ahmed S; Kragh-Hansen U; Otagiri M
AAPS PharmSciTech; 2000 May; 1(2):E12. PubMed ID: 14727845
[TBL] [Abstract][Full Text] [Related]
12. Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin.
Anguizola J; Debolt E; Suresh D; Hage DS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1021():175-181. PubMed ID: 26468085
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid binding to serum albumin: molecular simulation approaches.
Fujiwara S; Amisaki T
Biochim Biophys Acta; 2013 Dec; 1830(12):5427-34. PubMed ID: 23567799
[TBL] [Abstract][Full Text] [Related]
14. The fatty acid analogue 11-(dansylamino)undecanoic acid is a fluorescent probe for the bilirubin-binding sites of albumin and not for the high-affinity fatty acid-binding sites.
Wilton DC
Biochem J; 1990 Aug; 270(1):163-6. PubMed ID: 2396975
[TBL] [Abstract][Full Text] [Related]
15. Characterization of site I of human serum albumin using spectroscopic analyses: locational relations between regions Ib and Ic of site I.
Yamasaki K; Maruyama T; Takadate A; Suenaga A; Kragh-Hansen U; Otagiri M
J Pharm Sci; 2004 Dec; 93(12):3004-12. PubMed ID: 15468330
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals.
Basken NE; Mathias CJ; Green MA
J Pharm Sci; 2009 Jun; 98(6):2170-9. PubMed ID: 18937368
[TBL] [Abstract][Full Text] [Related]
17. NMR identification of endogenous metabolites interacting with fatted and non-fatted human serum albumin in blood plasma: Fatty acids influence the HSA-metabolite interaction.
Jupin M; Michiels PJ; Girard FC; Spraul M; Wijmenga SS
J Magn Reson; 2013 Mar; 228():81-94. PubMed ID: 23357430
[TBL] [Abstract][Full Text] [Related]
18. Characterization of drug-protein binding process by employing equilibrium sampling through hollow-fiber supported liquid membrane and Bjerrum and Scatchard plots.
Barri T; Trtić-Petrović T; Karlsson M; Jönsson JA
J Pharm Biomed Anal; 2008 Sep; 48(1):49-56. PubMed ID: 18565712
[TBL] [Abstract][Full Text] [Related]
19. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis.
Simard JR; Zunszain PA; Hamilton JA; Curry S
J Mol Biol; 2006 Aug; 361(2):336-51. PubMed ID: 16844140
[TBL] [Abstract][Full Text] [Related]
20. In vitro binding of leukotriene B4 (LTB4) to human serum albumin: evidence from spectroscopic, molecular modeling, and competitive displacement studies.
Zsila F; Bikádi Z; Lockwood SF
Bioorg Med Chem Lett; 2005 Aug; 15(16):3725-31. PubMed ID: 15993588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
